Abstract
Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced. © 2020 The Author(s).
Original language | English |
---|---|
Journal | Cardiovasc. Diabetol. |
Volume | 19 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- Diabetic kidney disease
- MACE
- SGLT-2 inhibitors
- Statin therapy
- Type 2 diabetes
- hydroxymethylglutaryl coenzyme A reductase inhibitor
- placebo
- renin inhibitor
- sodium glucose cotransporter 2 inhibitor
- albuminuria
- cardiovascular disease
- cardiovascular response
- cardiovascular risk
- diabetic nephropathy
- disease association
- disease severity
- drug efficacy
- estimated glomerular filtration rate
- high risk population
- human
- kidney function
- meta analysis
- non insulin dependent diabetes mellitus
- outcome assessment
- renal protection
- Review
- risk reduction
- adverse event
- chronic kidney failure
- clinical trial (topic)
- drug effect
- kidney
- pathophysiology
- protection
- risk assessment
- risk factor
- treatment outcome
- Cardiovascular Diseases
- Clinical Trials as Topic
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Kidney
- Protective Factors
- Renal Insufficiency, Chronic
- Risk Assessment
- Risk Factors
- Sodium-Glucose Transporter 2 Inhibitors
- Treatment Outcome